Skip to main content

Table 2 Glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and cytochrome P450 2D6 (CYP2D6) genotype and activity scores among RDT-positive participants screened and randomized; n (%)

From: Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial

 

Total RDT positives screened [n = 181]

Randomized to primaquine [n = 70]

Not randomized to primaquine [n = 70]

G6PD variant genotype

 A−

24 (14.0)

11 (16.7)

6 (9.0)

 A+

38 (22.1)

9 (13.6)

17 (25.4)

 B

110 (64.0)

46 (69.7)

44 (65.7)

G6PD phenotype (U/dL)

73 (51–91)

68 (51–89)

74 (40–90)

CYP2D6 variant genotype (activity score, ASa)

 *1/*1 (AS 2.0; EM)

129 (74.4)

48 (71.6)

49 (74.2)

 *1/*10 (AS 1.5; EM)

13 (7.6)

5 (7.5)

5 (7.6)

 *1/*17 (AS 1.5; EM)

18 (10.5)

8 (11.9)

8 (12.1)

 *1/*4 (AS 1.0; IM)

1 (0.6)

1 (1.5)

0 (0)

 *10/*17 (AS 1.0; IM)

3 (1.8)

2 (3.0)

0 (0)

 *17/*17 (AS 1.0; IM)

4 (2.3)

2 (3.0)

2 (3.0)

 *4/*10 (AS 0.5; IM)

1 (0.6)

0 (0)

1 (1.5)

 *4/*10/*17 (AS 1.0; IM)

2 (1.2)

1 (1.5)

1 (1.5)

  1. aCYP2D6 activity score is the sum of the per-allele scores; a null allele having a score of 0, a deficient allele a score of 0.5 and a normal allele a score of 1. CYP2D6 poor metabolizers (PM AS = 0), intermediate metabolizers (IM AS 0.5–1.0), extensive metabolizers (EM AS 1.5–2.0) [30, 31]